Oncolytics Biotech Inc (ONCY NASDAQ) stock market data APIs
$1.3497
-0.04(-3%)
as of September 17, 2025
Try our APIs with
free plan!
Oncolytics Biotech Inc Financial Data Overview
Price chart is built with
Anychart
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Prev. Close
1.3497
Open
1.3113
High
1.3683
Low
1.2741
52 wk Range
0.3258-1.53
Market Cap
137 M
Shares Outstanding
101 M
EPS
-0.07
Beta
1.187
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oncolytics Biotech Inc data using free add-ons & libraries
Get Oncolytics Biotech Inc Fundamental Data
Oncolytics Biotech Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -30 944 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-08
- EPS/Forecast: -0.0885
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oncolytics Biotech Inc News
New
Large-cap biotech is a sector to watch for investors: Analysts
Wall Street is looking for new ways to park cash in healthcare names, and large-cap biotechs have begun to gain steam. This asset class differs from traditional large-cap pharmaceutical companies —...
Oncolytics Biotech announces voting results from annual meeting
SAN DIEGO - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), whose stock has delivered an impressive 56% return year-to-date according to InvestingPro data, reported Monday that shareholders elected a...
Oncolytics Biotech GAAP EPS of -$0.07
* Oncolytics Biotech press release [https://seekingalpha.com/pr/20194961-oncolytics-biotech-reports-second-quarter-financial-results-and-details-clinical-program] (NASDAQ:ONCY [https://seekingalpha....
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
